Company intelligence
JJP Biologics
Next generation of novel biologics around companion diagnostics. Led by industry experts & backed by the Starak family.
About JJP Biologics
JJP Biologics is an innovative clinical-stage Polish biotechnology company developing novel biological therapies around established companion diagnostics. Our range of programs are in early stage development and we are actively seeking to cooperate with investors and academics on new or existing projects.
Verified activity
Signals from JJP Biologics
6 published signals
Research & Knowledge
JJP Biologics published evidence in a current publication showing that JJP-1008 blocks HVEM interactions with BTLA and CD160 while facilitating interaction with LIGHT.
Reported by JJP Biologics
Legal & Regulatory
JJP Biologics expects JJP-1008 to enter clinical studies still this year in 2026 as the second clinical molecule.
Reported by JJP Biologics
Presence & Recognition
JJP Biologics met Joanna Cygan and Beata Durzyńska from Rezon Bio during the Nordic Life Science Days to discuss European CDMO offerings.
Reported by Konstantin Matentzoglu
Research & Knowledge
JJP Biologics published a study showing that immunosuppressive signaling of HVEM through BTLA and CD160 is the greatest disadvantage of high HVEM expressing patients.
Reported by JJP Biologics
Products & Services
JJP Biologics expects JJP-1008 to enter clinical studies still this year in 2026 as the second clinical molecule.
Reported by JJP Biologics
Presence & Recognition
JJP Biologics CSO Dr. Louis Boon will provide a nebaprubart update in about 2 weeks in Brussels during BioTalk EU 2026
Reported by JJP Biologics